We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
6 peer-reviewed studies
What the evidence says
Most Colchicine studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2013–2025 with a typical study size of 5,522 participants.
Based on 6 studies · 1 meta-analysis · 4 RCTs · 6,054 total participants
Confidence
ModerateBy outcome
2 studies in the last 5 years · Latest meta-analysis: 2022
Low-dose colchicine reduced ischemic cardiovascular events after myocardial infarction (COLCOT).
Tardif, Kouz, Waters, Bertrand, Diaz, Maggioni · The New England journal of medicine (2019)
In LoDoCo2, low-dose colchicine (0.5 mg/day) reduced the risk of cardiovascular events in patients with chronic coronary disease.
Nidorf, Fiolet, Mosterd, Eikelboom, Schut, Opstal · The New England journal of medicine (2020)
In CLEAR-SYNERGY (OASIS-9), colchicine did NOT significantly reduce cardiovascular events after myocardial infarction.
Jolly, d'Entremont, Lee, Mian, Tyrwhitt, Kedev · The New England journal of medicine (2025)
Low-dose colchicine (0.5 mg/day) reduced cardiovascular events in patients with stable coronary disease.
Nidorf, Eikelboom, Budgeon, Thompson · Journal of the American College of Cardiology (2013)
Meta-analysis confirmed that colchicine reduces cardiovascular events in secondary prevention of coronary artery disease.
Xu, Mao, Liu, Lin, Zhang, Yang · Heart, lung & circulation (2022)
Colchicine's anti-inflammatory action targets the inflammatory basis of myocardial infarction and atherosclerosis.
Akodad, Sicard, Fauconnier, Roubille · Archives of cardiovascular diseases (2020)